

Stenting Design Is a Major Determinant of Outcomes in CAS

Pro!

Max Amor M.D

Cardio-Vascular Department

Clinic Louis Pasteur

Essey Les Nancy . France




8 The determinants of outcomes in CAS

- Good patient selection
- Good patient preparation
- Technical skill and virtuosity to access
- Good selection of the protecting device
- Good stent selection
- True and complete post dilatation under protection
- Fast procedure
- Good patient surveillance post procedure



Closed Cell Concept

Scaffolding





Stroke

Prevention

Structure

Radial Force



How to choose the most appropriate stent ?

Emmanuel Houdart

*Department of Interventional Neuroradiology
Hôpital Lariboisière
Paris, France*

Personal experience

- 125 Carotid Wall Stent (closed cells stent)
1 delayed ischemic stroke due to Clopidogrel resistance
- 40 Nitinol stents (open cells stent) : 2 delayed ischemic complications without Clopidogrel resistance

Mr Rai...left symptomatic stenosis



After nitinol stent implantation under filter deployment (no debris)



Pré





Post




Evolution

- Patient was discharged
- Recurrent TIA at day 8
- Echo-Doppler : normal stent patency, no intra-stent thrombosis





Failure of plaque exclusion was the suspected mechanism of delayed stroke in our patients

- Delayed embolism could occur if plaque (block of butter) protrudes through stent struts (wire able to cut the butter)



Cell's definition

- Elementary unit of a stent including the metallic struts and its void surface




Closed cells
interdependent cells



Open cells
independent cells






Surface of cells in mm²





Scaffolding

Stents are not equal, ...



the CWS cell size is 10 times smaller than the Acculink





CAS device selection

**A.
Cremonesi**
*

* Interventional Cardio-Angiology Unit
Villa Maria Cecilia Hospital
Cotignola (RA) - Italy

**F.
Castriota***

Symptomatic left ICA stenosis

■ **Male 85**

■ **CVRF:**

■ diabetes, hypertension

■ **Symptoms:**

■ recurrent TIAs

■ **Eco-Doppler:**

■ Left ICA 75% long lesion, PFV 2.3 m/sec


■ Dishomogeneous plaque, partially ulcerated, with significant soft component


■ **Medical therapy**

■ Beta-blocker

■ Plavix 75 mg


■ Aspirin 100 mg





- **EPD: Accunet 6.5 concentric filter**
- **Direct stenting: Protégé 7-10/40 mm**
- **Balloon: Maveric 5.0/20 mm @ 7 bars**



Final result



**Filling
defect?**

The complication: progressive plaque prolapse

min. 8 after stenting



Patient: asymptomatic


Plaque prolapse treatment

min. 20 after stenting

- EPD: Accunet 6.5
- **"Sandwich technique"**:
stent in stent to fix the
protruding plaque
between the two
frames
- Stent: XAct 8/30
- No post-dilatation



Second stent
implantation



Patient: asymptomatic

Plaque prolapse treatment


min. 21 after stenting



Patient: symptomatic for worsening right hemi-paresis!
Filter still in place!

In-hospital outcome

- The Patient developed a right hemi-paresis, successfully treated in ICU for two days.
- Neuro-rehabilitation for 20 days, with complete resolution of neurological deficits.
- Echo-Doppler: no evidence of significant plaque protrusion.



Stenting strategies to prevent peri-procedural complications

Carotid lesion / bifurcation issue	Type of stent
Plaque covering Long acting plaque prolapse prevention	Cobalt-alloy braided thread stent
In vessel flexibility Wall/plaque conformability	Nitinol open cell stents
Outward radial force Resistance to compression	Nitinol closed cell stents

CIRSE 2006

Carotid artery stenting

Do device characteristic affect outcome in carotid artery stenting?

M. Bosiers – P. Peeters



AZ St-Blasius, Dendermonde




Imelda Hospital, Bonheiden

Post-procedural phase (M.Bosiers)


ENDOVASCULAR → Plaque containment!

GARBAGE COMPACTOR



Distribution of Complications Over Time

Timing events




2/3 of all complications occurred in the post procedural phase

“Stent design” based analysis

ALL EVENTS	Total population		Symptomatic		Asymptomatic	
	n/N	%	n/N	%	n/N	%
Closed	51/2242	2.3%	21/934	2.2%	30/1308	2.3%
Open	39/937	4.2%	27/383	7.0%	12/554	2.2%
TOTAL	90/3179	2.8%	48/1317	3.6%	42/1862	2.6%

“Free cell area” based analysis



Does Free Cell Area Influence the Outcome in Carotid Artery Stenting?

M. Bosiers,^{1*} G. de Donato,² K. Deloose,¹ J. Verbist,³ P. Peeters,³
F. Castriota,⁴ A. Cremonesi⁴ and C. Setacci ⁴


Material and methods. A CAS database of 3179 consecutive CAS patients was retrospectively assessed. The distribution of neurological complications were analysed for association with the different stent types and designs. Events were subdivided into procedural and postprocedural events.

Results. The overall combined rate of TIA, stroke and death was 2.8% at 30 days (late events 1.9%). The post-procedural event rate analyzed for differences stents varied from 1.2% using BSCI Carotid Wallstent to 5.9% using Medtronic Exponent. The late event rates varied from 1.2% to 3.4% for free cell areas <2.5 mm² and >7.5 mm² respectively ($p < 0.05$). Post-procedural event rate was 1.3% for closed cells and 3.4% for open cells. All these differences were highly pronounced among symptomatic patients ($p < 0.0001$).

Conclusions. After carotid stenting, complication rates vary according to stent type, free cell area and cell design. In the symptomatic population (and also in the total population), post-procedural complication rates are highest for the open cell types and increase with larger free cell area.


Post-procedural phase




- The majority of strokes occur post-procedure (+/- 70%)



SPACE Clinical Trial

Sub Analysis



Procedure	Cell Design	MAE All Patients
Carotid Endarterectomy (CEA)		6.3% (37/584)
Carotid Artery Stent (CAS)	Closed Cell 	6.0% (26/434)
Carotid Artery Stent (CAS)	Open Cell 	11.0% (13/118)

“Stent design” based analysis

30-day MAE	Symptomatic	
	n/N	%
<u>BIC</u>		
Closed	21/934	2.2%
Open	27/383	7.0%
<u>SPACE</u>		
Closed	26/434	6.0%
Open	13/118	11.0%
CEA	37/584	6.3%

30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial

The SPACE Collaborative Group*

Summary

Background Carotid endarterectomy is effective in stroke prevention for patients with severe symptomatic carotid-artery stenosis, and carotid-artery stenting has been widely used as alternative treatment. Since equivalence or superiority has

Metl
isch:
end:
from
on ti
Curi

Find
rand
end:
0-05

Inter

for the periprocedural complication rate. The results of this trial do not justify the widespread use in the short-term of carotid-artery stenting for treatment of carotid-artery stenoses. Results at 6–24 months are awaited.

**Results confirmed by
subanalysis SPACE-trial
(Prof. Jansen)**


slent
rotid
leath
1-5%
ed at
3.

from
rotid
ity is

tomy


Closed Cell Concept

Scaffolding




Stroke
Prevention

Structure




Radial Force



Closed and Open Cell Geometry

Inner Lumen Images



Carotid
Wallstent™

Acculink™ Carotid
Stent


25% Lesion



Stent deployed in lumen representative of a vessel with a plaque protrusion infiltrating 25% of the internal diameter



70% Lesion

Stent deployed in lumen representative of a vessel with a plaque protrusion infiltrating 70% of the internal diameter





Immediate
disappearance of
the niche






Open cells protruding in the the ulcerated niche



“Stent design”: why closed cell?

- Open cell designs in tortuous curvature


PROLAPSE



“Stent design”: why closed cell?




FISH SCALING
at the concave surface
of the stent





Open-cell struts extending
beyond the intima with focal
contrast extravasation


Stentboost of an open cell stent at different phases



Chimney !



The open cell stent signature



- **External Carotid Bulging with or without teeth**
- **Scale protruding to the lumen or the wall**



First OCT cases Carotid Arteries Stents


Clinique Louis PASTEUR
Essey-les-Nancy / France
M.Amor –G.Ethevenot
F.Marty –J.P Simon –J Lemoine

Cases






- Target : Control post stenting Wallstent (autoexp. Stent) in internal carotid
- Positions of the struts
- Presence of materiel between the struts post stenting
- Definition of protocol to obtain images
- Case report will be made


Case 1




Case 1






**Protrusion of the
struts in the ulceration
niche.**



Case 2



Control post stenting




Floating struts and longer pullback – Protocol to obtain better flush is working.



Surprise Surprise Black & White






Case 3





Control Post stenting



Visualisation of malposition





Protrusion and material between struts





Future scaffolding solutions???

- Flexible *porous membrane* stent (+/- 100 μm ~ EPD)



Future scaffolding solutions???

- Flexible *porous membrane* stent



MembraX –
prototype
membrane stent
(Abbott
Vascular)


Pore size 80µm



Membrane stent
has potential for
reducing the late
emboli


Closed Cell Concept

Scaffolding




Stroke
Prevention

Structure



Radial Force



The relationship of post CAS hypotension to stent type – Dr. Katzen

Purpose

- To assess whether there is a significant difference in the incidence of peri-procedural hypotension requiring treatment related to stent type used in the carotid artery for de novo lesions.

Conclusion

Nitinol carotid stents exhibit 2x greater risk of peri-procedural hypotension than Carotid Wallstent.

Incidence of Hypotension	Nitinol ¹ (n=141)	Carotid Wallstent (n=31)	t-test
Periprocedural Hypotension	31.0%	12.9%	p=0.045
All Hypotension	40.4%	19.4%	p=0.014




The Pro M.H Wholey Esq



Outcome of carotid artery stenting at 2 years follow-up: comparison of nitinol open cell versus stainless steel closed cell stent design.

Maleux G, Marrannes J, Heye S, Daenens K, Verhamme P, Thijs V.
Department of Radiology, University Hospitals Leuven, Leuven, Belgium
J Cardiovasc Surg (Torino). 2009 Oct;50(5):669-75. Epub 2009 May 19

- **This was a non-randomized, retrospective study including 123 patients in whom 132 carotid stent-procedures were performed**
- **In 72 procedures a closed cell stainless steel stent was implanted, in the remaining 60 procedures an open cell nitinol stent was placed. In 8 patients with a stainless steel stent (11%) and in 6 patients with a nitinol stent (10%) a stroke occurred during the follow-up period (P=0.79).**
- **CONCLUSIONS:** At 2-year follow-up after carotid artery stenting, there is no difference in clinical outcome or in stent patency among patients treated with open versus closed cell design stents. Subsequently the type of carotid stent design does not seem to impact the overall midterm outcome after carotid artery stenting.



***Size of the cells
Only matters !***



Deformation of closed cells



A pocket is a deformable closed cell





**FORGET THE
DOG
BEWARE
OF OWNER!**